Assessment of the proliferative activity and radiosensitivity of human tumours using the cytokinesis-block micronucleus assay.
We established an in vitro cytokinesis-block micronucleus assay of human tumours for estimation of the proportion of cells undergoing mitosis (the dividing fraction, DF), the time for the number of nuclei to double and the radiosensitivity in terms of the micronucleus frequency, based on a concept described previously. Under certain conditions, the nuclear number doubling time (NNDT) was considered to represent the potential doubling time. Tumour specimens obtained at surgery were disaggregated into single-cell suspensions and were directly cultured in the presence of cytochalasin B with or without irradiation. At various intervals, the percentage of multinucleate cells (the plateau value represented the DF), the average number of nuclei per cell and the number of micronuclei in binucleate cells were determined. DF and NNDT values were obtained in 58 of the 73 tumours investigated, and the micronucleus frequency was obtained in 54 of these 58 tumours. The DF ranged from 4.1% to 71% and the NNDT ranged from 3.1 to 83 days. A DF > or = 20% was associated with a higher recurrence rate in patients undergoing curative operation. A correlation was found between the NNDT and the time to relapse in patients with recurrent disease. The average number of micronuclei per binucleate cell at 2 Gy of irradiation (after subtraction of the value at 0 Gy) ranged from 0.052 to 0.35. Tumours which produced more micronuclei after irradiation showed a better response to radiotherapy. This assay can be readily performed on human tumours and appears to have promise as a predictive assay for radiation therapy.
Shibamoto
Y
Y
Chest Disease Research Institute, Kyoto University, Japan.
Shibata
T
T
Miyatake
S
S
Oda
Y
Y
Manabe
T
T
Ohshio
G
G
Yagi
K
K
Streffer
C
C
Takahashi
M
M
Abe
M
M
D000230:Adenocarcinoma / Q000532:radiotherapy; D001932:Brain Neoplasms / Q000532:radiotherapy; D002277:Carcinoma / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002295:Carcinoma, Transitional Cell / Q000532:radiotherapy; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D002467:Cell Nucleus / Q000528:radiation effects*; D002470:Cell Survival / Q000528:radiation effects; D003571:Cytochalasin B / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D015162:Micronucleus Tests; D009369:Neoplasms / Q000532:radiotherapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D011836:Radiation Tolerance; D012074:Remission Induction; D012509:Sarcoma / Q000532:radiotherapy; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects*
D003571:Cytochalasin B